A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 May 2009 Planned number of patients changed from 43 to 18 as reported by ClinicalTrials.gov.
- 01 May 2009 Planned end date changed from 1 Jun 2010 to 1 Mar 2009 as reported by ClinicalTrials.gov.